TriSalus Life Sciences (TLSI) Expected to Announce Earnings on Tuesday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to announce its Q2 2025 earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $10.69 million for the quarter.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The company had revenue of $9.17 million for the quarter, compared to analysts’ expectations of $9.04 million. During the same period last year, the business posted ($0.60) EPS. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Stock Performance

Shares of TriSalus Life Sciences stock opened at $3.95 on Monday. The company has a market cap of $149.47 million, a P/E ratio of -3.53 and a beta of 0.48. TriSalus Life Sciences has a one year low of $3.46 and a one year high of $6.04. The firm has a fifty day moving average of $4.92 and a two-hundred day moving average of $5.25.

Insider Buying and Selling

In other TriSalus Life Sciences news, insider Richard Marshak sold 6,597 shares of the company’s stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the completion of the transaction, the insider owned 69,101 shares in the company, valued at approximately $357,943.18. This represents a 8.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 16,125 shares of company stock worth $83,528. 27.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

An institutional investor recently raised its position in TriSalus Life Sciences stock. Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) by 107.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 455,051 shares of the company’s stock after buying an additional 235,627 shares during the quarter. Geode Capital Management LLC owned 1.20% of TriSalus Life Sciences worth $2,480,000 as of its most recent filing with the SEC. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.